Our technology
Removing the molecules that shield tumours from the immune system
FOSCA BioTech is developing a patented platform that mechanically removes all cancer-promoting molecules simultaneously from the tumour microenvironment, addressing a key mechanism of immune evasion that current therapies cannot resolve.
The problem
Immune evasion runs on more than one pathway
Tumours suppress the immune system through multiple molecules at once. Conventional therapies target a single pathway, which leaves the others open.
The result is resistance: the tumour continues to evade the immune system through the pathways that remain.
Our solution
The principle of Interstitial ImmunoTherapy (IN'IT)
FOSCA has developed a device that targets all these components at once. The FOSCA device is a miniature probe that is implanted directly in the tumour and that extracts all the soluble components of the local microenvironment.
The mechanism
Multi-molecular targeting, by design
01
A patented intra-tumour probe
The FOSCA device is a miniature probe that is implanted directly in the tumour and that extracts all the soluble components of the local microenvironment. To prevent the tumour from quickly recreating its microenvironment, our probe can stay in place and function continuously over periods of several weeks once inserted.
02
Multiple effects against the tumour
By removing all soluble cancer-promoting molecules and microvesicles at the same time rather than blocking a single pathway, the long-term action of our probe has profound effects on the tumour. Its growth is stalled, its invasiveness and metastasis formation rate are reduced and it allows the immune system to regain access. Since immunosuppressive molecules are also cleared by our probe, the immune system can now recognise and attack the tumour.
03
A purely mechanical approach for no side-effects
Our probe extracts the tumour microenvironment without the need for any drug or synthetic molecule. It relies instead on chemo-physical mechanisms. The key resides in its capacity to function continuously over several weeks. This gives the time for the immune system to regain access to the tumour and mount a durable response to destroy it.
01
Pre-clinical programme underway
The functionality and efficacy of our probe has been extensively tested in 3D in vitro models and the in vivo programme has started in 2025 with promising results on the 3 key aspects: intra-tumour immune cells recruitment, slowing down of the tumour growth and reduction of metastasis rate.
02
Regulatory roadmap in place
Regulatory approval of our device is the cornerstone of our business roadmap. Our regulatory journey has started in 2026 and we have mapped the timings and budgets that will allow us to reach our first-in-human in 2029 and the market launch of a CE-marked device in 2032.
03
Intellectual property: a strong barrier to entry
We are carefully crafting our IP portfolio, covering all aspects of our device's functions and uses.
A technology platform for multiple difficult-to-treat cancer types
The tumour microenvironment is at the heart of the problem for most solid tumours: uncontrolled growth, metastasis, immune escape and resistance to treatment. The aggressiveness of difficult-to-treat cancers is linked to a very unfavourable microenvironment. Because of its mode of action our probe is designed to target these cancers, for which limited solutions can be offered to the patients. We will first apply it to the treatment of glioblastoma, a brain cancer for which current therapies can only offer a 14 month life expectancy. Our treatment strategy will then be deployed for the treatment of triple-negative breast cancer and pancreatic cancer.
Our mission
To transform cancer treatment by developing therapies that simultaneously target multiple cancer-promoting molecules.
Our vision
A world where cancer is treated effectively with minimal side effects.